Clinical Study Results
Research Sponsor: AstraZeneca AB
Treatment Studied: Durvalumab and tremelimumab
Study Purpose: This study was done to learn how durvalumab
and tremelimumab work in participants
with advanced or metastatic non-small
cell lung cancer
Protocol Number: D419AC00003
Thank you
Thank you to the participants and their families for taking part in the clinical study
for the study drugs durvalumab and tremelimumab. Durvalumab is also called
MEDI4736, and tremelimumab is also called MEDI1123.
You and all of the participants helped researchers learn more about durvalumab
and tremelimumab to help people with advanced or metastatic non-small cell
lung cancer, also called NSCLC.
AstraZeneca AB sponsored this study and believes it is important to share
the results of the study with you and the public. An independent non-profit
organization called CISCRP helped prepare this summary of the study results for
you. We hope it helps you understand and feel proud of your important role in
medical research.
If you participated in the study and have questions about the results, please
speak with the study doctor or staff at your study site.
1